| Views | |
|---|---|
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer | 69 |
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer | 7 | 31 | 1 | 3 | 4 | 12 | 11 |
| Views | |
|---|---|
| artconlli_a2018_tabernero_josep_phase II_study_Dual_EGFR.pdf | 17 |
| Views | |
|---|---|
| United States | 28 |
| China | 4 |
| Bulgaria | 3 |
| Spain | 3 |
| Belgium | 2 |
| South Korea | 1 |
| Views | |
|---|---|
| Menlo Park | 10 |
| Mountain View | 6 |
| Oakland | 5 |
| San Diego | 5 |
| Barcelona | 3 |
| Jackson | 2 |
| Shanghai | 2 |
| Guangzhou | 1 |
| Xingtai | 1 |